Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company focusing on neuromuscular and cardiac diseases, has granted 116,150 restricted stock units (RSUs) to four new employees. The RSUs will vest equally over four years, with 25% vesting on each anniversary of the grant date.
The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SLDB declined 2.21%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $456M at that time.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 116,150 restricted stock units (“RSUs”) to four newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many RSUs did Solid Biosciences (SLDB) grant to new employees in October 2025?
What is the vesting schedule for Solid Biosciences' (SLDB) October 2025 RSU grants?
Under which plan were the Solid Biosciences (SLDB) RSU grants issued?
What type of company is Solid Biosciences (SLDB)?
